20-F: Kamada and Kedrion Amend KEDRAB Distribution Agreement; Kamada Files Annual Report

Kamada Ltd. amends its KEDRAB distribution agreement with Kedrion Biopharma and files its annual report on Form 20-F.

Summary

• Kamada Ltd. and Kedrion Biopharma Inc. amended their KEDRAB distribution agreement, with Kedrion committing to purchase minimum quantities of KEDRAB from 2024 through 2027, projecting minimum aggregate revenues for Kamada of approximately $180.0 million.
• Kamada filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, with the Securities and Exchange Commission.
• The company expects to generate total revenues for the fiscal year 2025 in the range of $178 million to $182 million and adjusted EBITDA in the range of $38 million to $42 million.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with projected revenue and EBITDA growth, but also acknowledges risks and uncertainties associated with the business.

Positives

• Kedrion committed to purchasing minimum quantities of KEDRAB from 2024 through 2027, projecting minimum aggregate revenues for Kamada of approximately $180.0 million.
• The company expects to generate total revenues for the fiscal year 2025 in the range of $178 million to $182 million and adjusted EBITDA in the range of $38 million to $42 million.
• The midpoint of the projected 2025 revenue and adjusted EBITDA forecast represents a year-over-year increase of 12% in revenues and 17% in adjusted EBITDA.

Risks

• The document contains forward-looking statements that involve risks, assumptions and uncertainties.
• Kamada's business is currently highly concentrated on its two leading products, KEDRAB and CYTOGAM, and royalty income from GLASSIA sales by Takeda, so any adverse market event affecting these could have a material adverse effect.
• Kamada's long-term continued growth is dependent on its ability to engage in additional strategic transactions to acquire assets, businesses, products or technologies or engage in in-license or out-license transactions of products or technologies or form collaborations.
• Kamada relies on Kedrion for the sales of its KEDRAB product in the United States, and any disruption to this relationship would have an adverse effect on future results of operations and profitability.
• Kamada could become supply-constrained, and its financial performance could suffer, if it were unable to obtain adequate quantities of source plasma, plasma derivatives or specialty ancillary products.
• Kamada's business could be adversely affected by political, economic and military instability in Israel and its region.

Future Outlook

Kamada expects to generate total revenues for the fiscal year 2025 in the range of $178 million to $182 million and adjusted EBITDA in the range of $38 million to $42 million.

Industry Context

The announcement highlights Kamada's strategic focus on its core products and expansion into new markets, reflecting a broader trend in the biopharmaceutical industry towards specialization and strategic partnerships.

Comparison to Industry Standards

• Kamada's reliance on key products like KEDRAB and CYTOGAM is a common strategy in the biopharmaceutical industry, particularly for companies focused on niche markets.
• Competitors like CSL Behring and Grifols also focus on plasma-derived therapies, but have a broader portfolio and larger scale of operations.
• The projected revenue and EBITDA growth for 2025 indicates a positive outlook, but the company's success is heavily dependent on the performance of its key products and strategic partnerships.

Legal Proceedings

• Kamada is defending itself against a lawsuit filed by a third-party distributor related to the termination of a distribution agreement for Proprietary Products in Russia and Ukraine.

Stakeholder Impact

• Shareholders may benefit from the projected revenue and EBITDA growth and the special cash dividend.
• Employees may benefit from the company's continued investment in commercialization and development of new products.
• Customers may benefit from the company's efforts to improve existing products and develop new treatments for rare and serious conditions.

Next Steps

• Kamada plans to submit a revised statistical analysis plan (SAP) and study protocol for the InnovAATe study as an Investigational New Drug Application (IND) amendment during the second half of 2025.
• The company intends to conduct an interim futility analysis for the InnovAATe clinical study by the end of 2025.
• Kamada plans to complete recruitment for the InnovAATe study (Last Patient In) by the end of 2026 and complete the two years of treatment for the last enrolled patient (Last Patient Out) by the end of 2028.

Key Dates